Know-how, expertise available
I qualified as Engineer in Chemical Technology from the Higher Technical School Amsterdam (1971) and as MSc. in Biochemistry from the University of Amsterdam (1974). I have over 30 years of experience in (Bio)Pharmaceutical R&D at Organon; in the first 15 years heading a Laboratory in Biochemical Research and Development and as Program Coordinator Immunology. In 1990, I took up several positions at Akzo Nobel Pharma, all involved in corporate R&D management focusing on R&D strategy, formation of alliances and M&A. In 1995, I was appointed Executive Director of the Research Coordination Department at Akzo NobelPharma.
As Independent Consultant I am fulfilling various functions. Amongst others: Board Member of the Investment Fund Mibiton (secretary), Member of the Pre-Seed Grant Committee at NGI, Member of the Board of the Schering- Plough Pension Fund and the investment committee, advisor at Radboud Translational Medicine BV and member of the supervisory board of BioConnection BV.
As representative of Organon Biosciences/ AKZO Nobel Pharma I have been member of the Advisory Board of the Venture Capital Fund of Oxford Biosciences in Boston, USA, 1996-2009. I have been chairman of several task forces to set up and to get approval for public-private partnerships
such as the Top Institute Pharma (budget approved € 260 million, 2008), the Netherlands Genomics Institute I (budget approved € 290 million, 1999) and the Center of
Translational Molecular Medicine. Hans represented Akzo Nobel and Organon Biosciences as Board Member in public private partnerships (B-Basic, CTMM, BMM) and branche organizations such as NIABA and EuropaBio.
VandenBerg Advies is well suited to give advice on the strategic assessment of the product and business development of LS&H companies and detailing of BD plans.
The logical focus of my consultancy activities is within the field of Life Sciences and Health. The field is relatively broad ranging from development of pharmacotherapy, vaccines, diagnostic procedures and technologies and regenerative medicine approaches. Supporting technologies such as genomics and analytics are an integral part of the disciplines mentioned.